Abortion pills are the most common method of terminating pregnancies in the US.
Conservative Supreme Court justices wrote a scathing dissent to the 7-2 decision to allow women to continue accessing the abortion pill Mifepristone via mail and telehealth. "What is at stake is the perpetration of a scheme to undermine our decision in Dobbs v. Jackson," Justice Samuel Alito wrote in his dissent, referring to the decision that overturned…
A federal appeals court ruling against the Food and Drug Administration would have restricted access by mail to mifepristone.
A divided Supreme Court on Thursday indefinitely extended a freeze on strict new restrictions for dispensing the widely used abortion pill mifepristone while an underlying legal fight over the drug plays out.Why it matters: The widely expected order provides legal certainty for pharmacies, telehealth companies and clinicians caught up in the latest battle…
Abortion pills can remain available through the mail for the immediate future after the Supreme Court on Thursday paused a lower court ruling that would have blocked access while a lawsuit proceeds. The justices halted a May 1 order from the conservative U.S. Court of Appeals for the 5th Circuit that reinstated a requirement that women must visit a…
The high court’s decision allows providers to continue sending common abortion drug mifepristone to patients by mail.
The Supreme Court has maintained mail access to the abortion pill mifepristone, setting aside for now a lower court order that blocked abortion providers from prescribing the widely used drug through telehealth and shipping it to patients.
The Supreme Court kept broader access to abortion pill mifepristone in place, allowing telehealth prescribing and mail delivery to continue.
The Supreme Court on Thursday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restrictions while a lawsuit continues.
The Supreme Court restored access on Thursday to mail-order abortion pills nationwide, lifting an appeals court’s block on a 2023 FDA rule which had removed the in-person requirement for mifepristone. In an unsigned order, the high court ruled 7-2 in favor of issuing a stay, which indefinitely pauses a May 1 ruling by the U.S.…
